{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T15:02:06Z","timestamp":1648652526990},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Ropeg-Interferon als Standard der High- (und bald) Low-Risk-Polycythaemia-vera\u2002Bei der Polycythaemia vera (PV) steht mit Ropeg-Interferon erstmals eine zugelassene Therapieoption mit krankheitsmodifizierendem Effekt im Sinne einer deutlichen Reduktion der Allele-Last zur Verf\u00fcgung. Ropeg-Interferon ist damit Standard f\u00fcr die PV bei Indikation zur zytoreduktiven Therapie. Auch bei der Low-Risk-PV, die bisher \u201enur\u201c mit Aderl\u00e4ssen und niedrigdosierter Acetylsalicyls\u00e4ure ASS (100\u200amg) behandelt wurde, zeigt sich eine hohe Rate an Aderlass-Unabh\u00e4ngigkeit und auch ein molekulares Ansprechen. Das Paradigma, dass nur Hochrisiko-PV zytoreduktiv behandelt werden, wird in Zukunft mit hoher Wahrscheinlichkeit fallen.<\/jats:p><jats:p>\n          Neue JAK-Inhibitoren in der Myelofibrose bei Ruxolitinib-Versagen\/-Toxizit\u00e4t\u2002Fedratinib erzielt in der Behandlung der Myelofibrose eine Reduktion der Splenomegalie und der Symptomlast, auch in einer mit Ruxolitinib vorbehandelten Kohorte. Somit steht erstmals eine therapeutisch wirksame Alternative f\u00fcr Patienten zur Verf\u00fcgung, die Ruxolitinib-refrakt\u00e4r bzw. -intolerant sind.<\/jats:p><jats:p>\n          Myeloproliferative Neoplasien und sterile Entz\u00fcndungsprozesse\u2002Sterile Entz\u00fcndungsprozesse wie beispielsweise der Alarmin-Komplex spielen in der Pathogenese und Progression der MPN eine wesentliche Rolle. Hierbei werden inflammatorische Zytokine nicht nur von mutierten Zellen, sondern auch von nicht mutierten Umgebungszellen sezerniert; sie pr\u00e4gen den Krankheitsph\u00e4notyp und beg\u00fcnstigen die Entstehung und Expansion mutierter Subklone.<\/jats:p>","DOI":"10.1055\/a-1643-4357","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T23:42:17Z","timestamp":1647387737000},"page":"306-311","source":"Crossref","is-referenced-by-count":0,"title":["Entwicklungen im Verst\u00e4ndnis und der Behandlung myeloproliferativer Neoplasien"],"prefix":"10.1055","volume":"147","author":[{"given":"Stefan","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Innere Medizin V, H\u00e4matologie und Internistische Onkologie, Comprehensive Cancer Center Innsbruck (CCCI), Medizinische Universit\u00e4t Innsbruck (MUI), Innsbruck, \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Innere Medizin V, H\u00e4matologie und Internistische Onkologie, Comprehensive Cancer Center Innsbruck (CCCI), Medizinische Universit\u00e4t Innsbruck (MUI), Innsbruck, \u00d6sterreich"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"R Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"794240","DOI":"10.1155\/2011\/794240","article-title":"The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera","volume":"2011","author":"R Marchioli","year":"2011","journal-title":"Thrombosis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"H Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"F Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"M Griesshammer","year":"2018","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.2020005563","article-title":"JAK2-V617F and interferon-alpha induce megakaryocyte-biased stem cells characterized by decreased long-term functionality","volume":"137","author":"T N Rao","year":"2021","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"T Barbui","year":"2021","journal-title":"Lancet Haematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial","volume":"1","author":"A Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"C N Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/s2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"C N Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/s2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"R A Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial","volume":"4","author":"J Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis","volume":"35","author":"R A Mesa","year":"2017","journal-title":"J Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"C N Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/10781552211016078","article-title":"The regulatory saga of fedratinib","volume":"27","author":"S Khal","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"A Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"R Vaidya","year":"2012","journal-title":"Am J Hematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","article-title":"Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis","volume":"28","author":"N B Leimkuhler","year":"2021","journal-title":"Cell Stem cell"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"A G Fleischman","year":"2011","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"S Koschmieder","year":"2020","journal-title":"Blood Ref"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1643-4357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T23:43:03Z","timestamp":1647387783000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1643-4357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":20,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1643-4357","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}